Pulse Biosciences, Inc. (PLSE) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pulse Biosciences, Inc. on July 14, 2025. The filing discloses the appointment of a new Principal Accounting Officer and details the associated compensatory arrangements.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and equity grants.
Material Changes and Executive Appointment
On July 14, 2025, the Company appointed Mr. Steven T. Weber as Vice President of Accounting and Global Corporate Controller, effective immediately. Mr. Weber will also serve as the Company's Principal Accounting Officer. He brings over 25 years of finance experience, having previously served as Principal Accounting Officer for IGM Biosciences and Aeglea Biotherapeutics.
Compensatory Arrangements and Equity Grant
Mr. Weber entered into an at-will Employment Agreement dated July 11, 2025. His base salary and target bonus align with the Company's standard practices for Vice Presidents. Additionally, he received a "Start Date Option" to purchase 55,000 shares of common stock at an exercise price of $16.03 per share (the closing price on July 11, 2025).
The vesting schedule for the 55,000 options is structured as follows:
- Time-Based Vesting (50%): 27,500 shares vest over four years, with 25% vesting on each anniversary of the start date.
- Performance-Based Vesting (50%): The remaining 27,500 shares vest in four tranches of 6,875 shares each, contingent on the Company achieving specific market capitalization thresholds for 270 consecutive days:
- Tranche 1: Market cap of at least $1.5 billion (or by Dec 31, 2026).
- Tranche 2: Market cap of at least $2.25 billion (or by Dec 31, 2027).
- Tranche 3: Market cap of at least $3.0 billion (or by Dec 31, 2028).
- Tranche 4: Market cap of at least $4.0 billion (or by Dec 31, 2029).
Outlook, Risks, and Contingencies
The filing does not contain forward-looking guidance, risk factors, or contingencies beyond the standard terms of the employment agreement and equity plan. The performance-based vesting implies management's strategic focus on increasing the Company's market capitalization over the next four years.
Key Facts for Investor Verification
- Verify the current market capitalization of Pulse Biosciences relative to the $1.5B threshold required for the first tranche of performance-based options.
- Confirm the total number of shares authorized under the Amended and Restated 2017 Inducement Equity Incentive Plan to assess dilution impact.
- Review the Company's most recent 10-K or 10-Q for actual financial performance, as this 8-K contains no operational or financial results.
- Note the exercise price of $16.03 per share for the new grant and compare it to the current trading price of PLSE.